ANZCTR search results

Poor functioning in social activities, one of the most debilitating aspects of schizophrenia, is a core feature of this illness. Poor social functioning reinforces social isolation due to difficulties with communicating and understanding other people’s perspectives, as well as one’s own. It may also increase the risk of disease and death. Ninety percent of people with schizophrenia show poor social functioning even while in remission from their illness Improving social disability in schizophrenia is a high research priority world-wide, driven by consumers’ reports that it is one of their greatest unmet needs. Research suggests that impaired social cognition underlies poor social functioning. Social cognition is the mental operation that allows humans to think about and form impressions about other people in social interactions. Put simply it is people being able to think about other people. The aim of study was to determine the most effective way to treat poor social cognition in schizophrenia in order to improve real-world social functioning. We will do this by comparing the independent effects of two innovative social-cognitive remediation programs developed by us at the Macquarie Centre for Cognitive Science (MACCS): one targets poor emotion recognition (emotion recognition training; ERT) and the other targets poor ‘mental-state reasoning’ (i.e., reasoning about other people in terms of the others’ thoughts). We refer to the second program as mental-state reasoning training (without ERT: MSRT). We expected to see improvements in participants' social thinking and functioning in every day life.

Chronic pelvic pain is a frustrating condition for many women, having a variety of potential causes including endometriosis, adenomyosis, pelvic inflammatory disease, adhesions, irritable bowel syndrome and bladder pain syndrome (BPS). Endometriosis is considered the main cause with a prevalence of 70-90% in women with chronic pelvic pain. A number of recent trials have found that bladder pain syndrome also is an important differential diagnosis to consider with studies showing 53-89% of women with chronic pelvic pain have bladder pain syndrome. Similarly studies have also reported the high prevalence of having concomitant bladder pain syndrome and endometriosis with a study by Cheng et el in 2011, finding 60% of women with BPS also had endometriosis. This study aims to assess the impact of laparoscopy and more specifically surgical treatment of endometriosis on bladder pain syndrome. The study will use questionnaires preoperatively which will be compared at three, six and twelve months post procedure. The primary outcome measure will be bladder pain reduction at 12 months following endometriosis surgery with bladder pain reduction being defined as a >/=50% bladder pain reduction by the Visual Analogue Scale (VAS).

The study aims to evaluate the nutritional status of chemo-radiotherapy patients. Who is it for? You may be eligible to join this study if you are aged 18 years or over and are undergoing curative intent chemo-radiotherapy at the Alan Walker Cancer Care Centre in Darwin, Northern Territory. Trial details All participants in this study will have their nutritional status assessed at baseline, first week of treatment, then final week of treatment, and finally at 1-month post treatment using the Patient Generated-Subjective Global Assessment. This is a validated malnutrition assessment tool for cancer patients. This study aims to baseline the nutritional status of chemo-radiotherapy patients undergoing treatment at the Alan Walker Cancer Care Centre (Darwin), identify contributors to nutritional deterioration and determine if there is a difference between Indigenous and non-Indigenous patients. This study will provide a prospective analysis of malnutrition and a clear insight of nutritional status of cancer patients. This study will be the first of its kind to address the nutritional status of cancer patients in Indigenous Australians.

This study will evaluate the effectiveness of sleep education classes for high school students. As teenagers typically have a sleep pattern where they fall asleep late and wake up late, and which conflicts with getting up for school, this study will test 3 versions of sleep education classes against a control group (normal classes). These are: sleep education classes plus parent sleep education (SEC + P), sleep education classes plus light therapy (SEC + L) and sleep education classes plus parent sleep education plus light therapy (SEC + P + L). We expect that compared to the control classes that improvements in sleep and mood will occur in all 3 versions of the sleep education classes. We expect that the SEC + P + L will show the greatest improvements.

The main purpose of this study is to assess how safe and how well a topical solution, which is applied to the scalp of male participants who have a condition called male pattern baldness is tolerated. The secondary purpose is to assess how effective the topical solution is and also to assess the way the body absorbs, distributes and gets rid of the drug SM04554. .

To compare the pharmacokinetics of three IPX231 formulations administered subcutaneously as well as a single IPX231 formulation (IPX231-L0007) administered sublingually by two different methods: instillation via syringe versus spray in healthy adults.

The Safe-D study aims to determine the effectiveness of a mobile-based intervention to improve vitamin D levels in a cohort of young women, aged 16 to 25 years, residing in Victoria. The effectiveness of the mobile-based app will be compared with standard vitamin D supplementation (1000 IU daily, by mouth, capsule form) and general advice (in the form of a pamphlet). The study team hypothesise that the behavioural intervention will be as effective in correcting mild vitamin D deficiency within this cohort at 4 months as the standard pharmocological treatment.

The primary purpose of this study on healthy volunteers is to determine the safety and tolerability of two different formulations of study drug when administered via the intranasal route. There will be four study treatments: two active formulations and two placebos, or dummy treatments. Neither the study staff or the participants will know which treatment they are on. All formulations will be administered by the intranasal route using a single use nasal spray syringe. Each participant in each dose level group will receive two single doses of either both active drugs or both placebos, with the doses administered 48 hours apart via the nasal spray, in alternating nostrils.

The study is to evaluate the effectiveness of (i) Cognitive-behavioural therapy for insomnia in schizophrenia [CBT-I(S)] (ii) melatonin, (iii) a combination of CBT-I(S) and melatonin, and (iv) placebo, on insomnia symptoms, clinical symptoms, cognition, and functional health, in individuals with schizophrenia.

The purpose of this study is to assess safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy of F03 in subjects with mild cognitive impairment.